trending Market Intelligence /marketintelligence/en/news-insights/trending/ysKXETHzCNN2NA34pe-HZw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Maxigen Biotech swings to loss in Q1


ESG hits the mainstream for European private equity sponsors


What’s the Bottom Line: Credit Impact of COVID-19 on US Municipals


Banking Essentials Newsletter - February Edition, Part 2


Episode 1: Origins of 451 Research - Part 1

Maxigen Biotech swings to loss in Q1

Maxigen Biotech Inc. said its normalized net income for the first quarter came to a loss of 11 Taiwan cents per share, compared with the S&P Capital IQ consensus estimate of 4 cents per share.

The per-share result swung to a loss from the prior-year profit of 2 cents.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of NT$7.8 million, compared with income of NT$1.5 million in the prior-year period.

The normalized profit margin declined to negative 13.9% from 2.4% in the year-earlier period.

Total revenue fell 8.7% on an annual basis to NT$55.7 million from NT$61.1 million, and total operating expenses rose 12.5% year over year to NT$68.3 million from NT$60.7 million.

Reported net income totaled a loss of NT$12.7 million, or a loss of 18 cents per share, compared to income of NT$2.1 million, or 3 cents per share, in the prior-year period.

As of May 15, US$1 was equivalent to NT$30.44.